Korde, Neha

GPRC5D-Targeted CAR T Cells for Myeloma

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 411

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Landgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., et al. (2019) · JAMA Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 103

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial

Kazandjian, D., Hill, E., Dew, A., Morrison, C., Roswarski, J., Korde, N., Emanuel, M., Petrosyan, A., Bhutani, M., Calvo, K. R., et al. (2021) · JAMA Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 49

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Holkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., Baz, R., Korde, N., Lin, H.-Y., Chen, J.-Q., et al. (2016) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 48

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Mailankody, S., Diamonte, C., Fitzgerald, L., Kane, P., Wang, X., Sikder, D. S., Senechal, B., Bermudez, V. P., Frias, D., Morgan, J., et al. (2021) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30

Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma

Kazandjian, D., Diamond, B., Papadimitriou, M., Hill, E., Sklavenitis-Pistofidis, R., Ziccheddu, B., Blaney, P., Chojnacka, M., Durante, M., Maclachlan, K., et al. (2024) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Cirrincione, A. M., Poos, A. M., Ziccheddu, B., Kaddoura, M., Bärtsch, M.-A., Maclachlan, K., Chojnacka, M., Diamond, B., John, L., Reichert, P., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 15

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 14